This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Peroxisome proliferator-activated receptor 3D structures
From Proteopedia
3D Structures of PPAR
Updated on 23-August-2023 {{#tree:id=OrganizedByTopic|openlevels=0|
- PPARα;Ligand-binding domain 201-468
- 1k7l – hPPARα + G2409544 + NCOA1 - human
- 3e94 – hPPARα + fatty acid activator
- 4bcr, 5hyk - hPPARα + ligand
- 1kkq – hPPARα + GW6471 Antagonist + SMRT
- 2p54 - hPPARα + NCOA1
- 5azt - hPPARα (mutant) + NCOA1 peptide
- 2rew - hPPARα + azetidinone derivative activator
- 2znn, 2zno, 2znp, 2znq, 3kdu, 3vi8, 1i7g, 4bcr, 5hyk - hPPARα + agonist
- 3fei, 3fej, 3g8i, 3sp6, 6l96 - hPPARα + agonist + NCOA1 peptide
- 3sp6 - hPPARα + hPPARγ peptide + agonist
- 6kxx, 6kxy - hPPARα + peptide + agonist
- 7c6q - hPPARα + peptide + sanguinarine
- 3et1 - hPPARα + NCOA1 + indole derivative
- 6kb7, 6kba - hPPARα + pyrimidine derivative
- 7e5f, 7e5g, 7e5h, 7e5i - hPPARα + propanoic acid derivative
- 2npa - hPPARα + propanoic acid derivative + NCOA1
- 6jey, 6kax, 6kay, 6kaz ,6kb0, 6kb1, 6kb2, 6kb3, 6kb4 ,6kb5, 6kb6 ,6kb8, 6kb9, 6lx4, 6lx5, 6lx6, 6lx7, 6lx8, 6lx9, 6lxa, 6lxb, 6lxc - hPPARα + ampiphatic carboxylic acid derivative
- 7bpy, 7bpz, 7bq0, 7bq1, 7bq2, 7bq3, 7bq4 - hPPARα + NCOA1 + ampiphatic carboxylic acid derivative
- 6l38 - hPPARα + benzamide derivative
- 8hun, 8huo - hPPARα + anti-NASH drug
- 6kyp, 6l36, 6l37 - hPPARα + benzamide derivative + propanoic acid derivative
- 8huq, 8huk, 8hum - hPPARα + NCOA1 peptide + anti-NASH drug
- 1k7l – hPPARα + G2409544 + NCOA1 - human
- 5azt - hPPARα (mutant) + NCOA1 peptide
- 5azt - hPPARα (mutant) + NCOA1 peptide
- PPARγ;Ligand-binding domain 202-475
- 3prg, 2qmv, 1prg, 6l8b, 6vzo, 8cpj – hPPARγ
- 6fzy, 6fzg, 6t1s, 6vzn, 7cxe, 7e2o - hPPARγ (mutant)
- 2zk0, 2zk1, 2zk2, 2zk3, 2zk4, 2zk5, 2zk6, 3vjh, 3vji, 4e4k, 4e4q, 4jl4, 5hzc, 4ci5, 4ci4, 6an1, 2f4b, 1zeo, 2ath, 2hwq, 2hwr, 2i4j, 2q59, 2q8s, 3b3k, 3bc5, 3cds, 3g9e, 3gbk, 3gz9, 3ia6, 3kdt, 3an3, 3an4, 3noa, 3r5n, 3r8a, 3vso, 3vsp, 2xkw, 3b0q, 3ho0, 3hod, 1knu, 1i7i, 1nyx, 2pob, 5azv, 6f2l, 6c5t, 6c5q, 5wr1, 5wr0, 5wqx, 6md2, 6md4, 6md1, 6md0, 6mcz, 6k0t, 6avi, 6aug, 6qj5, 6t9c, 6tdc, 6vzl, 7lot, 7jqg, 7wox – hPPARγ + ligand
- 4l98, 4l96 - hPPARγ (mutant) + ligand
- 3r8i - hPPARγ + ureidofibrate derivative
- 6o67, 6o68, 6dgr, 6dgq, 6dgo, 6dgl, 6d8x, 6c1i - hPPARγ + agonist
- 2g0h, 2g0g, 2i4p, 2i4z, 2q5g, 2q5p, 2q5s, 2q61, 2q6r, 3cdp, 3d6d, 4em9, 4ema, 4prg, 2q6s, 5f9b, 4yt1, 3wmh, 6d3e, 6l89, 7p4e, 8dsz - hPPARγ + partial agonist
- [[7sqb, 8dsy hPPARγ + inverse agonist
- 2om9 - hPPARγ + cannabinoid
- 3b0r, 5lsg, 4r6s, 4r2u, 4r06, 6dh9, 6dcu, 6dbh - hPPARγ + antagonist
- 3osi, 3osw, 3pba - hPPARγ + bisphenol derivative
- 2p4y, 3adt, 3adu, 3adw, 3et3, 2hfp, 3ty0, 5two, 6fzj, 6t6b, 6y3u, 7a7h, 8aty, 8atz, 8cph, 8cpi - hPPARγ + modulator
- 2zvt - hPPARγ (mutant) + modulator
- 2vsr, 2vst, 2vv0, 2vv1, 2vv2, 2vv3, 2vv4, 3x1i, 3x1h, 3wj5, 3wj4, 3po9, 3sz1, 8bf2, 8bff - hPPARγ + fatty acid activator
- 6jey - hPPARγ + fatty acid
- 6jf0, 7efq - hPPARγ + fluorescent probe
- 6mcz, 6md0, 6md1, 6md2, 6qj5, 6t9c - hPPARγ + ligand
- 6tsg - hPPARγ + hormone
- 3ads, 3adx, 5u5l, 4xum, 4xuh, 4xta, 4xld, 6d5a, 6o67, 6o68, 7ahj, 7awc, 7awd, 7e0a - hPPARγ + anti-inflammatory drug
- 4oj4 - hPPARγ (mutant) + anti-inflammatory drug
- 3adv - hPPARγ + serotonin
- 3k8s, 3et0, 2yfe, 4a4v, 4a4w, 4jaz, 5tto, 4pwl, 4pvu, 5y2t, 5y2o, 5ugm, 6dha - hPPARγ + antidiabetic drug
- 4o8f, 6vzm - hPPARγ (mutant) + antidiabetic drug
- 6md4 - hPPARγ + oleic acid + antidiabetic drug
- 6enq - hPPARγ + antifibrotic drug
- 6zly - hPPARγ + valine derivative
- 3prg, 2qmv, 1prg, 6l8b, 6vzo, 8cpj – hPPARγ
- PPARγ complex with NCAO1
- 2gtk, 3qt0, 5gtp, 5gto, 5gtn, 5ycp, 5ycn, 5z6s, 5z5s, 6dgp, 6ilq, 6ijs, 6ijr, 6icj, 6jq7, 6ktm, 7cxf - hPPARγ + NCOA1 peptide
- 6t1v, 7cxg, 7cxh, 7cxi, 7cxj, 7cxk, 7cxl - hPPARγ (mutant) + NCOA1 peptide
- 6ktn - hPPARγ (mutant) + NCOA1 peptide + leukemia drug
- 3fur, 3kmg, 3v9t, 3v9v, 3v9y, 4f9m, 3b1m, 3lmp, 6fzp, 8dk4 - hPPARγ + NCOA1+ modulator
- 6fzf - hPPARγ (mutant) + NCOA1+ modulator
- 4fgy, 2prg - hPPARγ + antidiabetic drug + NCOA1 peptide
- 7wgo, 7wgq - hPPARγ + hyperlipidaemia drug + NCOA1 peptide
- 7wgp - hPPARγ + pancreatitis drug + NCOA1 peptide
- 6ad9 - hPPARγ + anticancer agent + NCOA1 peptide
- 6izm, 6izn, 8dkn - hPPARγ + pyridine derivative + NCOA1 peptide
- 3s9s, 3t03, 2fvj- hPPARγ + NCOA1 peptide + partial agonist
- 4y29, 2fvj, 5azt - hPPARγ + NCOA1 peptide + ligand
- 3h0a - hPPARγ + NCOA1 + retinoic acid receptor + retinoic acid + partial agonist
- 1k74, 1rdt, 1fm9 - hPPARγ + NCOA1 + retinoic acid receptor + retinoic acid + agonist
- 5ji0 - hPPARγ + retinoic acid receptor + NCOA1 peptide + antidiabetic drug
- 3vn2, 4hee, 4prg - hPPARγ + NCOA1 peptide + activator
- 2gtk, 3qt0, 5gtp, 5gto, 5gtn, 5ycp, 5ycn, 5z6s, 5z5s, 6dgp, 6ilq, 6ijs, 6ijr, 6icj, 6jq7, 6ktm, 7cxf - hPPARγ + NCOA1 peptide
- PPARγ complex with NCAO2
- 1wm0 – hPPARγ + NCAO2 peptide + agonist
- 5dwl, 5dvc, 5dv8, 5dv6, 5dv3, 5dsh - hPPARγ + NCAO2 peptide + inhibitor
- 7sqa, 8aqm, 8aqn, 8b8w, 8b8x, 8b8y, 8b90, 8b92, 8b93, 8b94, 8b95- hPPARγ + NCOA2 peptide + inverse agonist
- 8b8z, 8b91 - hPPARγ (mutant) + NCOA2 peptide + inverse agonist
- 3dzu, 3e00, 3dzy - hPPARγ + DNA + retinoic acid receptor + NCOA2 peptide + retinoic acid
- 1fm6 - hPPARγ + antidiabetic drug + retinoic acid receptor + NCOA2 peptide + retinoic acid
- 1wm0 – hPPARγ + NCAO2 peptide + agonist
- PPARγ complex with other proteins
- 1zgy – hPPARγ + antidiabetic drug + nuclear receptor peptide
- 3cs8, 3u9q, 8bf1 - hPPARγ + PGC-1A peptide
- 3cwd - hPPARγ + SRC1-2
- 6oni, 6pdz - hPPARγ +inverse agonist + NCOR peptide
- 6ms7 - hPPARγ + PGC1 LXXLL + modulator
- 6d94 - hPPARγ + mediator of RNA polymerase II peptide
- 6onj - hPPARγ + mediator of RNA polymerase II peptide + antidiabetic drug
- 7rle - hPPARγ + CREB-binding protein peptide + agonist
- 1zgy – hPPARγ + antidiabetic drug + nuclear receptor peptide
- PPARδ;Ligand-binding domain 171-441
- 2gwx – hPPARδ
- 2env – hPPARδ zinc finger domain 72-146 - NMR
- 2baw, 2b50, 2awh – hPPARδ + Vaccenic Acid
- 3gwx – hPPARδ + 5,8,11,14,17-Eicosapentaenoic Acid
- 3dy6 – hPPARδ + anthranilic acid
- 3et2, 1gwx – hPPARδ + fatty acid
- 2j14, 2xyj, 2xyw, 2xyx, 3oz0, 3sp9, 5u3q, 5u3r, 5u3s, 5u3t, 5u3u, 5u3v, 5u3w, 5u3x, 5u3y, 5u3z, 5u40, 5u41, 5u42, 5u43, 5u44, 5u45, 1gwx, 3tkm, 1y0s, 5u46, 5y7x, 7vwf, 7vwg, 7vwh, 7w0g, 7wgn, 8hul - hPPARδ + agonist
- 3peq - hPPARδ + partial agonist
- 3d5f - hPPARδ + phenoxy derivative
- 5xmx, 6a6p, 5zxi, 7f80 - hPPARδ + inhibitor
- 7wgl - hPPARd + hyperlipidaemia drug
- 2gwx – hPPARδ
}}
